Table 4

Current disease modifying antirheumatic drug (DMARD) treatment in outpatients with RA in rheumatological care with respect to disease severity (1998; values are percentages)

	Mild (n=2861)	Moderate (n=4164)	Severe (n=1672)
Single treatments
Antimalarial drugs^4-150	15.6^4-150	7.4	1.7^4-150
SSZ^4-150 ^4-151	12.1^4-150	9.1	3.5^4-150
Parenteral gold^4-150	8.4^4-150	4.2	3.3
MTX^4-150 ^4-151	33.2^4-150	48.8	42.7^4-150
AZA^4-150 ^4-151	1.7^4-150	3.1	5.1^4-150
Other DMARDs	5.1^4-150	3.9	5.7
Combination treatments
MTX with Antimalarial drugs^4-150	2.1^4-150	5.0	8.7^4-150
MTX with SSZ^4-150	1.2^4-150	3.6	5.1
Other combinations with MTX^4-150	2.3^4-150	4.4	10.9^4-150
Combinations without MTX^4-150	0.9^4-150	2.0	3.3
Total of combinations^4-150	6.4^4-150	15.1	28.1^4-150
Total
Antimalarial drugs^4-150	18.5^4-150	14.4	13.7
SSZ	13.9	14.1	10.9
MTX^4-150	38.7^4-150	62.0	67.9^4-150
Any DMARD^4-150	82.5^4-150	91.7	90.3

↵4-150 Differences from “moderate” are significant at the 0.001 level.
↵4-151 SSZ = sulfasalazine; MTX = methotrexate; AZA = azathioprine.